不可切除恶性胸膜间皮瘤患者一线纳武利尤单抗联合伊匹木单抗对比化疗:CheckMate 743研究3年结局
III期CheckMate 743研究3年随访更新显示,不可切除恶性胸膜间皮瘤患者一线纳武利尤单抗联合伊匹木单抗对比化疗,中位总生存期18.1个月对14.1个月(HR 0.73,95%CI 0.61-0.87),3年总生存率23%对15%,未观察到新的安全性信号。
要点
- 中位随访43.1个月,联合治疗组中位OS 18.1个月,化疗组14.1个月,HR 0.73(95%CI 0.61-0.87)。
- 3年OS率联合组23%对化疗组15%;3年PFS率14%对1%;ORR 40%对44%。
- 因治疗相关不良事件停用联合治疗者中位OS 25.4个月,34%的缓解者缓解持续≥3年。
核心结论
- 至少3年随访确认,纳武利尤单抗联合伊匹木单抗对比化疗持续提供长期生存获益且安全性可控,支持该方案作为不可切除恶性胸膜间皮瘤的标准治疗,不受组织学类型限制。
研究设计与样本
- III期CheckMate 743研究(NCT02899299),既往未治疗、组织学确诊、不可切除恶性胸膜间皮瘤且ECOG体能状态≤1的成人患者按1:1随机分组。
- 联合组接受纳武利尤单抗3 mg/kg每2周联合伊匹木单抗1 mg/kg每6周,最长2年;化疗组接受六周期铂类联合培美曲塞化疗。
- 本次报告包含更新疗效与安全性、探索性生物标志物分析(四基因炎症表达特征评分)及因治疗相关不良事件停药患者的post hoc疗效分析。
主要发现
- 中位随访43.1个月,联合组对比化疗组中位OS为18.1个月对14.1个月(HR 0.73,95%CI 0.61-0.87),3年OS率23%对15%。
- 联合组对比化疗组3年PFS率14%对1%,ORR 40%对44%;3年时联合组28%的缓解者与化疗组0%的缓解者仍有持续缓解。
- 各亚组(包括按组织学类型)均观察到联合治疗对比化疗的生存获益改善。
- 四基因炎症特征高评分似乎与联合治疗更好的生存获益相关。
- 联合治疗未观察到新的安全性信号,尽管患者已停药1年。
临床怎么用
- 作者结论支持纳武利尤单抗联合伊匹木单抗作为不可切除恶性胸膜间皮瘤的标准治疗,不受组织学类型限制。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In the phase III CheckMate 743 study (NCT02899299), first-line nivolumab plus ipilimumab significantly improved overall survival (OS) versus chemotherapy in patients with unresectable malignant pleural mesothelioma (MPM). We report updated data with 3-year minimum follow-up. PATIENTS AND METHODS: Adults with previously untreated, histologically confirmed, unresectable MPM and Eastern Cooperative Oncology Group performance status of ≤1 were randomized 1 : 1 to nivolumab (3 mg/kg every 2 weeks) plus ipilimumab (1 mg/kg every 6 weeks) for up to 2 years, or six cycles of platinum plus pemetrexed chemotherapy. This report includes updated efficacy and safety outcomes, exploratory biomarker analyses including four-gene inflammatory expression signature score, and a post hoc efficacy analysis in patients who discontinued treatment due to treatment-related adverse events (TRAEs). RESULTS: With a median follow-up of 43.1 months, nivolumab plus ipilimumab continued to prolong OS versus chemotherapy. Median OS was 18.1 versus 14.1 months [hazard ratio (95% confidence interval), 0.73 (0.61-0.87)], and 3-year OS rates were 23% versus 15%, respectively. Three-year progression-free survival rates were 14% versus 1%, and objective response rates were 40% versus 44%. At 3 years, 28% versus 0% of responders had an ongoing response. Improved survival benefit with nivolumab plus ipilimumab versus chemotherapy was observed across subgroups, including histology. A high score of the four-gene inflammatory signature appeared to correlate with improved survival benefit with nivolumab plus ipilimumab. No new safety signals were observed with nivolumab plus ipilimumab, despite patients being off therapy for 1 year. In patients who discontinued nivolumab plus ipilimumab due to TRAEs, median OS was 25.4 months, and 34% of responders maintained their responses for ≥3 years after discontinuation. CONCLUSIONS: With 3 years' minimum follow-up, nivolumab plus ipilimumab continued to provide long-term survival benefit over chemotherapy and a manageable safety profile, supporting the regimen as standard-of-care treatment for unresectable MPM, regardless of histology.
引用
- Peters S, Scherpereel A, Cornelissen R, et al. First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743. Ann Oncol. 2022. PMID: 35124183. doi:10.1016/j.annonc.2022.01.074
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。